Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015

Details for Mechanism ID: 13309
Country/Region: Kenya
Year: 2014
Main Partner: Kenya Medical Research Institute
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $4,491,178 Additional Pipeline Funding: $1,209,345

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The Kenya Medical Research Institute (KEMRI) is the Kenyan Government’s health research agency. KEMRI’s goal is to conduct HIV implementation science and innovative surveillance through the platform of delivering high-quality HIV care and treatment and prevention services, and field surveys. Activities are focused in the high prevalence counties of western Kenya, particularly Kisumu county’s regional referral hospital (“JOOTRH”) and the KEMRI/CDC Health and Demographic Surveillance System (HDSS) in Siaya County. In Nairobi county, KEMRI supports Tabitha clinic in Kibera and HIV testing and counselling in the Mathare slums. While most programs attend those seeking HIV services at these public locations, specific projects also target fisherfolks, people who inject drugs and those affected by gender-based violence.

KEMRI supports innovative development of data systems to improve patient care, program functioning and provide “lessons learned” about what works in HIV care. KEMRI service delivery covers adult and pediatric HIV care and treatment, Prevention of Mother to Child Transmission (PMTCT), TB/HIV, and Provider Initiated Testing and Counseling (PITC) at JOOTRH. KEMRI has also supported regional clinical activities such as viral load testing, Early Infant Diagnosis, Kaposi Sarcoma treatment and support for a community model of multi-drug resistant TB treatment. The project aligns with Kenya National Strategic Plan strategies and closely with health facility leadership and county authorities to further the adoption of evaluation findings into policy. Strategies to reduce cost include business management system reviews, expenditure analysis and engagement of county governments to prioritize/allocate funds.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $192,369
Care: TB/HIV (HVTB) $567,380
Care: Pediatric Care and Support (PDCS) $106,572
Laboratory Infrastructure (HLAB) $1,400,000
Strategic Information (HVSI) $589,034
Biomedical Prevention: Injection Safety (HMIN) $350,000
Sexual Prevention: Abstinence/Be Faithful (HVAB) $50,000
Testing: HIV Testing and Counseling (HVCT) $236,588
Sexual Prevention: Other Sexual Prevention (HVOP) $205,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $195,590
Treatment: Adult Treatment (HTXS) $450,000
Treatment: Pediatric Treatment (PDTX) $148,645
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D By Age: <15 2015 803
C2.1.D By Age: 15+ 2015 8,096
C2.1.D By Age/Sex: <15 Female 2015 402
C2.1.D By Age/Sex: <15 Male 2015 401
C2.1.D By Age/Sex: 15+ Female 2015 5,343
C2.1.D By Age/Sex: 15+ Male 2015 2,753
C2.1.D By Sex: Female 2015 5,745
C2.1.D By Sex: Male 2015 3,154
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 8,899
C2.1.D Sum of Age disaggregates 2015 8,899
C2.1.D Sum of Age/Sex disaggregates 2015 8,899
C2.1.D Sum of Sex disaggregates 2015 8,899
C2.1.D_NGI By Age: <15 2015 803
C2.1.D_NGI By Age: 15+ 2015 8,096
C2.1.D_NGI By Age/Sex: <15 Female 2015 402
C2.1.D_NGI By Age/Sex: <15 Male 2015 401
C2.1.D_NGI By Age/Sex: 15+ Female 2015 5,343
C2.1.D_NGI By Age/Sex: 15+ Male 2015 2,753
C2.1.D_NGI By Sex: Female 2015 5,745
C2.1.D_NGI By Sex: Male 2015 3,154
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 8,899
C2.1.D_NGI Sum of Age disaggregates 2015 8,899
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 8,899
C2.1.D_NGI Sum of Sex disaggregates 2015 8,899
C2.4.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 8,899
C2.4.D Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 8,454
C2.5.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 8,899
C2.5.D Number of HIV-positive patients in HIV care who started TB treatment 2015 169
CARE_CURR Age/sex: <1 Female 2015 13
CARE_CURR Age/sex: <1 Male 2015 13
CARE_CURR Age/sex: 1-4 Female 2015 87
CARE_CURR Age/sex: 1-4 Male 2015 92
CARE_CURR Age/sex: 10-14 Female 2015 121
CARE_CURR Age/sex: 10-14 Male 2015 122
CARE_CURR Age/sex: 15-19 Female 2015 107
CARE_CURR Age/sex: 15-19 Male 2015 65
CARE_CURR Age/sex: 20-24 Female 2015 444
CARE_CURR Age/sex: 20-24 Male 2015 120
CARE_CURR Age/sex: 25-49 Female 2015 3,795
CARE_CURR Age/sex: 25-49 Male 2015 1,806
CARE_CURR Age/sex: 5-9 Female 2015 160
CARE_CURR Age/sex: 5-9 Male 2015 155
CARE_CURR Age/sex: 50+ Female 2015 730
CARE_CURR Age/sex: 50+ Male 2015 624
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 381
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 382
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 5,076
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 2,615
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 8,454
CARE_CURR Sum of Age/Sex disaggregates 2015 8,454
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 8,454
CARE_NEW Age/sex: <1 Female 2015 2
CARE_NEW Age/sex: <1 Male 2015 2
CARE_NEW Age/sex: 1-4 Female 2015 16
CARE_NEW Age/sex: 1-4 Male 2015 17
CARE_NEW Age/sex: 10-14 Female 2015 22
CARE_NEW Age/sex: 10-14 Male 2015 22
CARE_NEW Age/sex: 15-19 Female 2015 23
CARE_NEW Age/sex: 15-19 Male 2015 10
CARE_NEW Age/sex: 20-24 Female 2015 42
CARE_NEW Age/sex: 20-24 Male 2015 42
CARE_NEW Age/sex: 25-49 Female 2015 637
CARE_NEW Age/sex: 25-49 Male 2015 356
CARE_NEW Age/sex: 5-9 Female 2015 29
CARE_NEW Age/sex: 5-9 Male 2015 28
CARE_NEW Age/sex: 50+ Female 2015 221
CARE_NEW Age/sex: 50+ Male 2015 68
CARE_NEW Aggregated Age/sex: <15 Female 2015 69
CARE_NEW Aggregated Age/sex: <15 Male 2015 69
CARE_NEW Aggregated Age/sex: 15+ Female 2015 923
CARE_NEW Aggregated Age/sex: 15+ Male 2015 476
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 1,537
CARE_NEW Sum of Age/sex disaggregates 2015 1,537
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 1,537
CARE_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 2
CARE_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services 2015 2
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 2
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 2
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 2
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
FN_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 2
FN_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 2
FN_SITE Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 2
FN_SITE Sum of Numerator Support Type disaggregates 2015 2
FN_SITE Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 2
FN_SITE_den Sum of Denominator Support Type disaggregates 2015 2
FN_THER Age: <1 2015 4
FN_THER Age: 1-4 2015 29
FN_THER Age: 15-17 2015 27
FN_THER Age: 18+ 2015 1,185
FN_THER Age: 5-14 2015 90
FN_THER Aggregated Age: <18 2015 150
FN_THER Aggregated Age: 18+ 2015 1,185
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2015 1,335
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2015 1,780
FN_THER Sum of Age disaggregates 2015 1,335
FN_THER Sum of Aggregated Age disaggregates 2015 1,335
FPINT_SITE By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 2
FPINT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points 2015 2
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 2
FPINT_SITE Service delivery type: Clinical 2015 2
FPINT_SITE Sum of Numerator Site Support Type disaggregates 2015 2
FPINT_SITE Sum of Service Delivery Type disaggregates 2015 2
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2015 2
FPINT_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
GEND_GBV Age: 0-9 2015 115
GEND_GBV Age: 10-14 2015 108
GEND_GBV Age: 15-17 2015 65
GEND_GBV Age: 18-24 2015 252
GEND_GBV Age: 25+ 2015 180
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 576
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 302
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 418
GEND_GBV Number of people receiving post-GBV care 2015 720
GEND_GBV Sex: Female 2015 548
GEND_GBV Sex: Male 2015 172
GEND_GBV Sum of Age disaggregates 2015 720
GEND_GBV Sum of Sex disaggregates 2015 720
HTS_TST Age/sex: 1-4 Female 2015 2,177
HTS_TST Age/sex: 1-4 Female 2015 2,177
HTS_TST Age/sex: 1-4 Male 2015 2,177
HTS_TST Age/sex: 1-4 Male 2015 2,177
HTS_TST Age/sex: 10-14 Female 2015 1,555
HTS_TST Age/sex: 10-14 Female 2015 1,555
HTS_TST Age/sex: 10-14 Male 2015 1,555
HTS_TST Age/sex: 10-14 Male 2015 1,555
HTS_TST Age/sex: 15-19 Female 2015 3,110
HTS_TST Age/sex: 15-19 Female 2015 3,110
HTS_TST Age/sex: 15-19 Male 2015 3,110
HTS_TST Age/sex: 15-19 Male 2015 3,110
HTS_TST Age/sex: 20-24 Female 2015 7,775
HTS_TST Age/sex: 20-24 Female 2015 7,775
HTS_TST Age/sex: 20-24 Male 2015 7,775
HTS_TST Age/sex: 20-24 Male 2015 7,775
HTS_TST Age/sex: 25-49 Female 2015 12,438
HTS_TST Age/sex: 25-49 Female 2015 12,438
HTS_TST Age/sex: 25-49 Male 2015 12,438
HTS_TST Age/sex: 25-49 Male 2015 12,438
HTS_TST Age/sex: 5-9 Female 2015 933
HTS_TST Age/sex: 5-9 Female 2015 933
HTS_TST Age/sex: 5-9 Male 2015 933
HTS_TST Age/sex: 5-9 Male 2015 933
HTS_TST Age/sex: 50+ Female 2015 3,110
HTS_TST Age/sex: 50+ Female 2015 3,110
HTS_TST Age/sex: 50+ Male 2015 3,110
HTS_TST Age/sex: 50+ Male 2015 3,110
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 4,665
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 4,665
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 26,433
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 26,433
HTS_TST Aggregated Age/sex: <15 Female 2015 4,665
HTS_TST Aggregated Age/sex: <15 Male 2015 4,665
HTS_TST Aggregated Age/sex: 15+ Female 2015 26,433
HTS_TST Aggregated Age/sex: 15+ Male 2015 26,433
HTS_TST By Test Result: Negative 2015 59,708
HTS_TST By Test Result: Negative 2015 59,708
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 62,196
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 62,196
HTS_TST Sum of Age/Sex disaggregates 2015 62,196
HTS_TST Sum of Age/Sex disaggregates 2015 62,196
HTS_TST Sum of Aggregated Age/Sex <15 2015 9,330
HTS_TST Sum of Aggregated Age/Sex <15 2015 9,330
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 52,866
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 52,866
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 62,196
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 62,196
HTS_TST Sum of Test Result disaggregates 2015 62,196
HTS_TST Sum of Test Result disaggregates 2015 62,196
HTS_TST_POS By Test Result: Positive 2015 2,488
HTS_TST_POS By Test Result: Positive 2015 2,488
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 7
LAB_ACC By site support type: Technical Assistance-only (TA) 2015 10
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 17
LAB_ACC Sum of Support Type disaggregates 2015 17
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 10
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 10
LAB_CAP Sum of Site Support Type disaggregates 2015 10
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 41
LAB_PT CD4: Number of laboratories that participate in this PT program 2015 54
LAB_PT CD4: Number of laboratories that perform this testing 2015 255
LAB_PT Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program 2015 75
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 19
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program 2015 25
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing 2015 1,450
PMTCT_ARV Life-long ART (including Option B+) 2015 921
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 307
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,228
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,228
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 491
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 430
PMTCT_ARV Sum of New and Current disaggregates 2015 921
PMTCT_ARV Sum of Regimen Type disaggregates 2015 1,228
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 921
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 307
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,228
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,228
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 491
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 430
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 921
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 1,228
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 737
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 245
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 49
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 1,228
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 982
PMTCT_EID Sum of Infant Age disaggregates 2015 982
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 2
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 2
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 2
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 2
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 2
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 2
PMTCT_STAT By: Known positives at entry 2015 577
PMTCT_STAT By: Number of new positives identified 2015 651
PMTCT_STAT Number of new ANC and L&D clients 2015 4,270
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 4,270
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,228
PMTCT_STAT_NGI By: Known positives at entry 2015 577
PMTCT_STAT_NGI By: Number of new positives identified 2015 651
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 4,270
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 4,270
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,228
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 2
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 2
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 2
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 2
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 2
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 2
SITE_SUPP By program area/support type: Food and Nutrition Direct Service Delivery (DSD) 2015 2
SITE_SUPP By program area/support type: General Population Prevention Direct Service Delivery (DSD) 2015 1
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 1
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 5
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 12
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) 2015 2
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 2
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 2
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 2
SITE_SUPP Number of unique sites supported by PEPFAR 2015 2
TB_ART Age: 0-4 2015 9
TB_ART Age: 15+ 2015 345
TB_ART Age: 5-14 2015 26
TB_ART Aggregated Age: <15 2015 35
TB_ART Aggregated Age: 15+ 2015 345
TB_ART Female 2015 175
TB_ART Known HIV-positive 2015 152
TB_ART Male 2015 205
TB_ART Newly tested 2015 228
TB_ART Sum of Aggregated Age disaggregates 2015 380
TB_ART Sum of Sex disaggregates 2015 380
TB_ART Sum of Test Status disaggregates 2015 380
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 423
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 380
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 2
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 2
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 2
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 2
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 2
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 2
TB_SCREEN Age: <1 2015 26
TB_SCREEN Age: 1-4 2015 173
TB_SCREEN Age: 10-14 2015 236
TB_SCREEN Age: 15-19 2015 162
TB_SCREEN Age: 20-24 2015 541
TB_SCREEN Age: 25-49 2015 5,319
TB_SCREEN Age: 5-9 2015 306
TB_SCREEN Age: 50+ 2015 1,269
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 741
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 7,291
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 8,454
TB_SCREEN Sex: Female 2015 5,183
TB_SCREEN Sex: Male 2015 2,849
TB_SCREEN Sum of Age disaggregates 2015 903
TB_SCREEN Sum of Aggregated Age disaggregates 2015 8,032
TB_SCREEN Sum of Sex disaggregates 2015 8,032
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 8,032
TX_CURR Age/Sex: <1 Female 2015 11
TX_CURR Age/Sex: <1 Male 2015 11
TX_CURR Age/Sex: 1-4 Female 2015 77
TX_CURR Age/Sex: 1-4 Male 2015 77
TX_CURR Age/Sex: 15+ Female 2015 4,306
TX_CURR Age/Sex: 15+ Male 2015 2,319
TX_CURR Age/Sex: 5-14 Female 2015 240
TX_CURR Age/Sex: 5-14 Male 2015 240
TX_CURR Aggregated Age/Sex: <1 Female 2015 11
TX_CURR Aggregated Age/Sex: <1 Male 2015 11
TX_CURR Aggregated Age/Sex: <15 Female 2015 328
TX_CURR Aggregated Age/Sex: <15 Male 2015 328
TX_CURR Aggregated Age/Sex: 15+ Female 2015 4,306
TX_CURR Aggregated Age/Sex: 15+ Male 2015 2,319
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 7,281
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 82
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 81
TX_CURR Sum of age/sex disaggregates 2015 656
TX_CURR Sum of Aggregated Age/Sex <15 2015 656
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 6,625
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 7,281
TX_CURR_NGI Age/Sex: <1 Female 2015 11
TX_CURR_NGI Age/Sex: <1 Male 2015 11
TX_CURR_NGI Age/Sex: 1-4 Female 2015 77
TX_CURR_NGI Age/Sex: 1-4 Male 2015 77
TX_CURR_NGI Age/Sex: 15+ Female 2015 4,306
TX_CURR_NGI Age/Sex: 15+ Male 2015 2,319
TX_CURR_NGI Age/Sex: 5-14 Female 2015 240
TX_CURR_NGI Age/Sex: 5-14 Male 2015 240
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 11
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 11
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 328
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 328
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 4,306
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 2,319
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 7,281
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 7,281
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 656
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 6,625
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 7,281
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 2
TX_DIST Total number of PEPFAR supported District Health Offices 2015 2
TX_NEW Aggregated Grouping by Age: <1 Male 2015 29
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 29
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 97
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 98
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 776
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 418
TX_NEW Breastfeeding status 2015 43
TX_NEW By Age/Sex: <1 Female 2015 29
TX_NEW By Age/Sex: <1 Male 2015 29
TX_NEW By Age/Sex: 1-4 Female 2015 17
TX_NEW By Age/Sex: 1-4 Male 2015 17
TX_NEW By Age/Sex: 10-14 Female 2015 22
TX_NEW By Age/Sex: 10-14 Male 2015 23
TX_NEW By Age/Sex: 15-19 Female 2015 16
TX_NEW By Age/Sex: 15-19 Male 2015 10
TX_NEW By Age/Sex: 20-24 Female 2015 68
TX_NEW By Age/Sex: 20-24 Male 2015 19
TX_NEW By Age/Sex: 25-49 Female 2015 580
TX_NEW By Age/Sex: 25-49 Male 2015 288
TX_NEW By Age/Sex: 5-9 Female 2015 29
TX_NEW By Age/Sex: 5-9 Male 2015 29
TX_NEW By Age/Sex: 50+ Female 2015 112
TX_NEW By Age/Sex: 50+ Male 2015 101
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 1,389
TX_NEW Pregnancy status 2015 387
TX_NEW Sum of Age/Sex disaggregates 2015 1,389
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 1,389
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 30
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,086
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 81
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 110
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,086
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 1,197
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 767
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 1,408
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 35
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,278
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 95
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 130
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,278
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 903
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 2
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 2
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 2
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 2
TX_SITE Total number of PEPFAR-supported ART sites 2015 2
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
Cross Cutting Budget Categories and Known Amounts Total: $982,199
Human Resources for Health $688,253
Gender: Gender Based Violence (GBV) $186,473
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Monitoring and Evaluation
Gender: Gender Equality $81,973
Changing harmful gender norms and promoting positive gender norms
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Implementation
Capacity building
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Monitoring and Evaluation
Condoms: Policy, Tools, and Services $25,500
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning